Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crescent Biopharma (CBIO) Gains from Sales and Divestitures (2016 - 2025)

Crescent Biopharma (CBIO) has disclosed Gains from Sales and Divestitures for 8 consecutive years, with $48133.0 as the latest value for Q1 2025.

  • On a quarterly basis, Gains from Sales and Divestitures fell 17.84% to $48133.0 in Q1 2025 year-over-year; TTM through Mar 2025 was $48133.0, a 17.84% decrease, with the full-year FY2023 number at $68055.0, down 38.16% from a year prior.
  • Gains from Sales and Divestitures was $48133.0 for Q1 2025 at Crescent Biopharma, down from $58581.0 in the prior quarter.
  • In the past five years, Gains from Sales and Divestitures ranged from a high of $189792.0 in Q3 2021 to a low of $48133.0 in Q1 2025.
  • A 5-year average of $91741.4 and a median of $68055.0 in 2023 define the central range for Gains from Sales and Divestitures.
  • Peak YoY movement for Gains from Sales and Divestitures: skyrocketed 82.32% in 2021, then plummeted 42.02% in 2022.
  • Crescent Biopharma's Gains from Sales and Divestitures stood at $189792.0 in 2021, then tumbled by 42.02% to $110050.0 in 2022, then crashed by 38.16% to $68055.0 in 2023, then decreased by 13.92% to $58581.0 in 2024, then dropped by 17.84% to $48133.0 in 2025.
  • Per Business Quant, the three most recent readings for CBIO's Gains from Sales and Divestitures are $48133.0 (Q1 2025), $58581.0 (Q3 2024), and $58581.0 (Q2 2024).